|
Vol 49(2015) N 4 p. 513-519; DOI 10.1134/S0026893315040172 E.S. Starodubova1*, O.V. Preobrazhenskaia1, Y.V. Kuzmenko1, A.A. Latanova1, E.I. Yarygina2, V.L. Karpov1 Rabies vaccines: Current status and prospects for development 1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia2Skryabin Moscow State Academy of Veterinary Medicine and Biotechnology, Moscow, 109472 Russia *estarodubova@yandex.ru Received - 2014-11-07; Accepted - 2015-02-05 Rabies is an infectious disease among humans and animals that remains incurable, despite its longstanding research history. The only way to prevent the disease is prompt treatment, including vaccination as an obligatory component and administration of antirabies immunoglobulin as a supplement. Since the first antirabies vaccination performed in the 19th century, a large number of different rabies vaccines have been developed. Progress in molecular biology and biotechnology enabled the development of effective and safe technologies of vaccine production. Currently, new-generation vaccines are being developed based on recombinant rabies virus strains or on the production of an individual recombinant rabies antigen-glycoprotein (G protein), either as a component of nonpathogenic viruses, or in plants, or in the form of DNA vaccines. In this review, the main modern trends in the development of rabies vaccines have been discussed. rabies, rabies vaccine, glycoprotein |